Development of novel nanoparticles shelled with heparin for berberine delivery to treat Helicobacter pylori.
Various approaches have been proposed to overcome the unpleasant side-effects associated with antibiotic treatment for Helicobacter pylori. The limited effectiveness of such approaches has forced researchers to consider alternative strategies to eliminate H. pylori infection. The plant alkaloid berberine is known to significantly reduce proliferation of H. pylori. To localize berberine to the site of H. pylori infection, this study developed a novel nanoparticle berberine carrier with a heparin shell. Analysis of a simulated gastrointestinal medium indicated that the proposed in vitro drug carrier system effectively controlled the release of berberine, which interacted specifically with the intercellular space at the site of H. pylori infection. Furthermore, the prepared nanoparticles significantly increased the suppressive effect of berberine on H. pylori growth while efficiently reducing cytotoxic effects in H. pylori-infected cells.